Literature DB >> 28598712

Autotaxin Expression in Hepatocellular Carcinoma.

Ilker Memet1,2, Evanthia Tsalkidou1,2, Alexandra K Tsaroucha1,2, Maria Lambropoulou3, Ekaterini Chatzaki4, Gregory Trypsianis5, Dimitrios Schizas6, Michael Pitiakoudis1,2, Constantinos Simopoulos1,2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Despite the important progress observed in liver surgery, the survival rates are discouraging. The aim of this study was to investigate the expression of autotaxin in hepatocellular carcinoma.
MATERIALS AND METHODS: Liver tissues from 28 human hepatocellular carcinomas were evaluated for the expression of autotaxin by immunohistochemistry. The gender, age, histological grade, lymphovascular invasion, number of tumors, levels of serum alpha-fetoprotein (aFP), presence of liver cirrhosis, hepatitis, surgery and survival rates were recorded.
RESULTS: Immunohistochemistry confirmed the expression of autotaxin in hepatocellular carcinoma. The histological grade seems to be the only independent predictor of stronger autotaxin expression, as significantly higher levels of autotaxin were detected in histological grades II and III. In addition, levels of autotaxin seem to be the most important independent prognostic factor related to poor survival. There was an eight-fold higher risk of death in patients with high levels of autotaxin compared to patients with low levels.
CONCLUSIONS: Autotaxin expression in hepatocellular carcinoma could be of great importance. High autotaxin expression in HCC is detected in patients with histological grade II and III. Further, patients with elevated expression levels were found to possess an eight-fold higher risk of death. Autotaxin role in HCC should be further elucidated.

Entities:  

Keywords:  aFP; autotaxin; hepatocellular carcinoma; histological grade; immunohistochemistry; survival rate

Mesh:

Substances:

Year:  2017        PMID: 28598712     DOI: 10.1080/08941939.2017.1331280

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  7 in total

Review 1.  Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer.

Authors:  Sha She; Qian Zhang; Jinzhi Shi; Fan Yang; Kai Dai
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

2.  Hepatic autotaxin overexpression in infants with biliary atresia.

Authors:  Wanvisa Udomsinprasert; Paisarn Vejchapipat; Naruemon Klaikeaw; Voranush Chongsrisawat; Yong Poovorawan; Sittisak Honsawek
Journal:  PeerJ       Date:  2018-07-24       Impact factor: 2.984

Review 3.  Lipid Phosphate Phosphatases and Cancer.

Authors:  Xiaoyun Tang; David N Brindley
Journal:  Biomolecules       Date:  2020-09-02

4.  ENPP2 Methylation in Health and Cancer.

Authors:  Maria Panagopoulou; Dionysios Fanidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

Review 5.  KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.

Authors:  Shuo Wang; Jiang Chen; Xiao-Zhong Guo
Journal:  World J Gastrointest Oncol       Date:  2022-08-15

Review 6.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

7.  Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis.

Authors:  Lei Zhou; Juanni Li; Xing Liu; Yongzhong Tang; Tunliang Li; Huiyin Deng; Jia Chen; Xinlin Yin; Kuan Hu; Wen Ouyang
Journal:  Cell Death Discov       Date:  2022-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.